These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 23584268)
1. CD133 is a selective marker of CRC? Del Rio P; Bonati E; Crafa P; Campanini N; Montana Montana C; Bezer L; Dell'Abate P; Sianesi M Minerva Chir; 2013 Feb; 68(1):87-95. PubMed ID: 23584268 [TBL] [Abstract][Full Text] [Related]
2. CD133 expression is correlated with poor prognosis in colorectal cancer. Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343 [TBL] [Abstract][Full Text] [Related]
3. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425 [TBL] [Abstract][Full Text] [Related]
4. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status. Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031 [TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. Xi HQ; Zhao P J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057 [TBL] [Abstract][Full Text] [Related]
6. AC133 expression associated with poor prognosis in stage II colorectal cancer. Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518 [TBL] [Abstract][Full Text] [Related]
7. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy. Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065 [TBL] [Abstract][Full Text] [Related]
8. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089 [TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer. Hongo K; Kazama S; Sunami E; Tsuno NH; Takahashi K; Nagawa H; Kitayama J Med Oncol; 2012 Dec; 29(4):2849-57. PubMed ID: 22246526 [TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373 [TBL] [Abstract][Full Text] [Related]
12. Circulating CD133(+)/ESA(+) cells in colorectal cancer patients. Tseng JY; Yang CY; Yang SH; Lin JK; Lin CH; Jiang JK J Surg Res; 2015 Dec; 199(2):362-70. PubMed ID: 26119272 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Horst D; Kriegl L; Engel J; Kirchner T; Jung A Cancer Invest; 2009 Oct; 27(8):844-50. PubMed ID: 19626493 [TBL] [Abstract][Full Text] [Related]
15. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients. Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044 [TBL] [Abstract][Full Text] [Related]
16. Clinical implications of periostin in the liver metastasis of colorectal cancer. Wu G; Wang X; Zhang X Cancer Biother Radiopharm; 2013 May; 28(4):298-302. PubMed ID: 23347152 [TBL] [Abstract][Full Text] [Related]
17. CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer. Horst D; Kriegl L; Engel J; Jung A; Kirchner T Eur J Cancer; 2009 Jul; 45(11):2034-40. PubMed ID: 19403300 [TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of CD133 expression in gastric carcinoma. Ishigami S; Ueno S; Arigami T; Uchikado Y; Setoyama T; Arima H; Kita Y; Kurahara H; Okumura H; Matsumoto M; Kijima Y; Natsugoe S Anticancer Res; 2010 Jun; 30(6):2453-7. PubMed ID: 20651407 [TBL] [Abstract][Full Text] [Related]
19. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment. Lönnroth C; Andersson M; Nordgren S; Lundholm K Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]